NASDAQ:IMCC - Nasdaq - CA44969Q4060 - Common Stock - Currency: USD
2.16
-0.02 (-0.92%)
The current stock price of IMCC is 2.16 USD. In the past month the price decreased by -5.26%. In the past year, price increased by 8.76%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
PFE | PFIZER INC | 8.46 | 149.04B | ||
SNY | SANOFI-ADR | 13.58 | 136.54B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
ZTS | ZOETIS INC | 27.1 | 72.39B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
IM Cannabis Corp is a CA-based company operating in Pharmaceuticals industry. The company is headquartered in Toronto, Ontario and currently employs 95 full-time employees. The company went IPO on 2019-11-05. IM Cannabis Corp. is a Canada-based international cannabis company that provides cannabis products to medical patients in Israel and Germany. The firm's ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging proprietary data and patient insights. The firm also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel. In Germany, the Company operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. The company offers four different product lines, leading with the Craft Collection which offers the highest quality Canadian craft cannabis flower. The firm's other product lines include Top-Shelf Collection, Signature Collection and Full Spectrum Extracts. The firm's brands include The WAGNERS, BLKMKT, LOT420, and The PICO collection (minis).
IM CANNABIS CORP
1 Adelaide Street East, Unit 801
TORONTO ONTARIO CA
CEO: Oren Shuster
Employees: 95
Company Website: https://imcannabis.com/
Investor Relations: http://investors.imcannabis.com
Phone: 14162564202
The current stock price of IMCC is 2.16 USD. The price decreased by -0.92% in the last trading session.
The exchange symbol of IM CANNABIS CORP is IMCC and it is listed on the Nasdaq exchange.
IMCC stock is listed on the Nasdaq exchange.
IM CANNABIS CORP (IMCC) has a market capitalization of 6.67M USD. This makes IMCC a Nano Cap stock.
IM CANNABIS CORP (IMCC) currently has 95 employees.
IM CANNABIS CORP (IMCC) has a support level at 1.99 and a resistance level at 2.17. Check the full technical report for a detailed analysis of IMCC support and resistance levels.
The Revenue of IM CANNABIS CORP (IMCC) is expected to grow by 19.16% in the next year. Check the estimates tab for more information on the IMCC EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
IMCC does not pay a dividend.
IM CANNABIS CORP (IMCC) will report earnings on 2025-03-26, before the market open.
IM CANNABIS CORP (IMCC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.28).
The outstanding short interest for IM CANNABIS CORP (IMCC) is 0.95% of its float. Check the ownership tab for more information on the IMCC short interest.
ChartMill assigns a fundamental rating of 2 / 10 to IMCC. Both the profitability and financial health of IMCC have multiple concerns.
Over the last trailing twelve months IMCC reported a non-GAAP Earnings per Share(EPS) of -3.28. The EPS decreased by -172.51% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -28.82% | ||
ROE | -216.04% | ||
Debt/Equity | 2.24 |
ChartMill assigns a Buy % Consensus number of 83% to IMCC. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of -314.48% and a revenue growth 19.16% for IMCC